completed

The objective of the TIDE study was to evaluate the effect of treatment with thiazolidineiones (TZD) on cardiovascular morbidity and mortality, and was expected to be the definitive trial regarding the role of TZDs in the prevention of cardiovascular events in people with type 2 diabetes mellitus.

Primary endpoint:

The composite of CV death, non-fatal MI, non-fatal stroke, and significant heart failure.

Secondary endpoints:

The composite of CV death, nonfatal myocardial infarction, or nonfatal stroke, revascularization, hospitalization for congestive heart failure; total mortality; cardiovascular mortality; major coronary heart disease events, total strokes, microvascular complications of diabetes.

All endpoints wrere adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, treatment, open label, parallel group

NO. of Countries

35

NO. of Sites

350

NO. of Participants

16000

Study Period

2009-2011

Sponsor

PHRI

Back To Top